BCB-276

BCB-276 is a CAR-T cell therapy developed by BrainChild Bio. Its target is B7-H3 (the sponsor names B7-H3). The sponsor states: An autologous CAR T-cell therapy targeting B7-H3, an antigen described as universally expressed in diffuse intrinsic pontine glioma (DIPG), manufactured from the patient's own leukapheresed immune cells after standard radiation therapy. ClinicalTrials.gov describes the intervention as: Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in glioma & glioblastoma. The largest, NCT07680439, plans to enrol 75 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.